title: Adverse event reports following yellow fever vaccination, 2007-13.
abstract: BACKGROUND
  Yellow fever (YF) vaccines have been available since the 1930s and are generally considered safe and effective. However, rare reports of serious adverse events (SAE) following vaccination have prompted the Advisory Committee for Immunization Practices to periodically expand the list of conditions considered contraindications and precautions to vaccination.
  
  
  METHODS
  We describe adverse events following YF vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 2007 through 2013 and calculate age- and sex-specific reporting rates of all SAE, anaphylaxis, YF vaccine-associated neurologic disease (YEL-AND) and YF vaccine-associated viscerotropic disease (YEL-AVD).
  
  
  RESULTS
  There were 938 adverse events following YF vaccination reported to VAERS from 2007 through 2013. Of these, 84 (9%) were classified as SAEs for a rate of 3.8 per 100 000 doses distributed. Reporting rates of SAEs increased with increasing age with a rate of 6.5 per 100 000 in persons aged 60-69 years and 10.3 for ≥70 years. The reporting rate for anaphylaxis was 1.3 per 100 000 doses distributed and was highest in persons ≤18 years (2.7 per 100 000). Reporting rates of YEL-AND and YEL-AVD were 0.8 and 0.3 per 100 000 doses distributed, respectively; both rates increased with increasing age.
  
  
  CONCLUSIONS
  These findings reinforce the generally acceptable safety profile of YF vaccine, but highlight the importance of continued physician and traveller education regarding the risks and benefits of YF vaccination, particularly for older travellers.
authors.affiliation: Arboviral Diseases Branch, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, USA.
authors.forename: Nicole P
authors.initials: NP
authors.lastname: Lindsey
authors.affiliation: Arboviral Diseases Branch, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, USA.
authors.forename: Ingrid B
authors.initials: IB
authors.lastname: Rabe
authors.affiliation: Immunization Safety Office, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30333, USA.
authors.forename: Elaine R
authors.initials: ER
authors.lastname: Miller
authors.affiliation: Arboviral Diseases Branch, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, USA.
authors.forename: Marc
authors.initials: M
authors.lastname: Fischer
authors.affiliation: Arboviral Diseases Branch, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, USA.
authors.forename: J Erin
authors.initials: JE
authors.lastname: Staples
mesh_terms: D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008875:Middle Aged; D060735:Pharmacovigilance; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment; D014481:United States; D014611:Vaccination / Q000009:adverse effects; D015004:Yellow Fever / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D055815:Young Adult
chemical_list: D022341:Yellow Fever Vaccine
keywords: VAERS; Yellow fever; adverse event; vaccine